核酸
向性
低密度脂蛋白受体
免疫系统
小分子
髓系细胞
受体
脂质体
化学
脂蛋白
生物
细胞生物学
生物化学
病毒学
胆固醇
免疫学
病毒
作者
Cheng Lin,Alexander Jans,Justina Clarinda Wolters,Mohamed Ramadan Mohamed,Emiel P. C. van der Vorst,Christian Trautwein,Matthias Bartneck
标识
DOI:10.1002/adhm.202202670
摘要
Abstract Hepatic clearance of lipid nanoparticles (LNP) with encapsulated nucleic acids restricts their therapeutic applicability. Therefore, tools for regulating hepatic clearance are of high interest for nucleic acid delivery. To this end, this work employs wild‐type (WT) and low‐density lipoprotein receptor (Ldlr)−/− mice pretreated with either a leukotriene B4 receptor inhibitor (BLT1i) or a high‐density lipoprotein receptor inhibitor (HDLRi) prior to the injection of siRNA‐LNP. This work is able to demonstrate significantly increased hepatic uptake of siRNA‐LNP by the BLT1i in Ldlr−/− mice by in vivo imaging and discover an induction of specific uptake‐related proteins. Irrespective of the inhibitors and Ldlr deficiency, the siRNA‐LNP induced RNA‐binding and transport‐related proteins in liver, including haptoglobin (HP) that is also identified as most upregulated serum protein. This work observes a downregulation of proteins functioning in hepatic detoxification and of serum opsonins. Most strikingly, the HDLRi reduces hepatic uptake and increases siRNA accumulation in spleen and myeloid immune cells of blood and liver. RNA sequencing demonstrates leukocyte recruitment by the siRNA‐LNP and the HDLRi through induction of chemokine ligands in liver tissue. The data provide insights into key mechanisms of siRNA‐LNP biodistribution and indicate that the HDLRi has potential for extrahepatic and leukocyte targeting.
科研通智能强力驱动
Strongly Powered by AbleSci AI